Refine my results

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†

Gerber, B. ; Loibl, S. ; Eidtmann, H. ; Rezai, M. ; Fasching, P. A. ; Tesch, H. ; Eggemann, H. ; Schrader, I. ; Kittel, K. ; Hanusch, C. ; Kreienberg, R. ; Solbach, C. ; Jackisch, C. ; Kunz, G. ; Blohmer, J. U. ; Huober, J. ; Hauschild, M. ; Nekljudova, V. ; Untch, M. ; von Minckwitz, G.

In: Annals of Oncology, 2013, vol. 24, no. 12, p. 2978-2984